Ironwood Pharma (IRWD) Misses Q4 EPS by 19c, provides guidance

Ironwood Pharma (NASDAQ: IRWD) reported Q4 EPS of $0.00, $0.19 worse than the analyst estimate of $0.19. Revenue for the quarter came in at $117.55 million versus the consensus estimate of $117.91 million.

GUIDANCE:

Ironwood Pharma sees Q1 2024 revenue of $435-455 million, versus the consensus of $462.9 million.

For earnings history and earnings-related data on Ironwood Pharma (IRWD) click here.

You May Also Be Interested In

• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
• Deutsche Bank Starts DexCom (DXCM) at Buy
• BofA lists top 5 themes driving next $1tn in incremental semi sales